Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in the world. Mitochondrial fission regulator 2 (MTFR2) is involved in the development of various cancers. However, the roles of MTFR2 in HCC remain unknown. In this study, we conducted a comprehensive analysis of MTFR2 in HCC, which was generated from integrative MTFR2 analyses of eight HCC cell lines, and three datasets (public dataset, real-world dataset, and immunotherapy dataset) derived from bulk HCC tissues, survival, and immunotherapy data. We demonstrated that the expression level of MTFR2 is upregulated in HCC, leading to poor prognosis. MTFR2 is positively correlated with the level of immune cell infiltration, multiple immune checkpoints and immunotherapy response prediction pathways, and acts as an important role in cancer-immunity cycle. In conclusion, our work indicates that MTFR2 can shape a barrier of immune microenvironment and result in poor prognosis in hepatocellular carcinoma, but the immune barrier may be broken by immunotherapy.

中文翻译：

---

MTFR2在肝细胞癌中形成免疫微环境屏障

肝细胞癌（HCC）是世界上癌症相关死亡的主要原因。线粒体裂变调节因子 2 (MTFR2) 参与多种癌症的发生。然而，MTFR2 在 HCC 中的作用仍不清楚。在这项研究中，我们对 HCC 中的 MTFR2 进行了全面分析，该分析是通过对八种 HCC 细胞系的综合 MTFR2 分析生成的，以及来自大量 HCC 组织、生存数据的三个数据集（公共数据集、真实世界数据集和免疫治疗数据集）。和免疫治疗数据。我们证明 MTFR2 的表达水平在 HCC 中上调，导致预后不良。 MTFR2与免疫细胞浸润水平、多个免疫检查点和免疫治疗反应预测途径呈正相关，在癌症免疫循环中发挥重要作用。总之，我们的工作表明MTFR2可以形成免疫微环境屏障并导致肝细胞癌预后不良，但免疫疗法可能会打破免疫屏障。